=> d abs fbib fhitstr 1-5

L4 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2009 ACS on STN

AB Aqueous gel formulations, including an immune response modifier (IRM), such as those chosen from imidazoquinoline amines, tetrahydroimidazoquinoline amines, imidazopyridine amines, 6,7-fused cycloalkylimidazopyridine amines, 1,2 -bridged imidazoquinoline amines, imidazonaphthyridine amines, imidazotetrahydronaphthyridine amines, oxazoloquinoline amines, thiazoloquinoline amines, oxazolopyridine amines, thiazolopyridine amines, oxazolonaphthyridine amines, thiazolonaphthyridine amines, pyrazolopyridine amines, pyrazoloquinoline amines, tetrahydropyrazoloquinoline amines, pyrazolonaphthyridine amines, tetrahydropyrazolonaphthyridine amines, and 1 H-imidazo dimers fused to pyridine amines, quinoline amines, tetrahydroquinoline amines, naphthyridine amines, or tetrahydronaphthyridine amines, are provided. Methods of use and kits are also provided. For example, gel was prepared containing 4-(4-amino-2-propyl-1H-imidazo[4,5-c]quinolin-1-yl)-N-propylbutyramide 0.1%, 0.25N ethanesulfonic acid 0.594%, Carbomer 974P 2.1%, propylene glycol 15%, methylparaben 0.15%, propylparaben 0.03%, edetate disodium 0.05%, 20% tromethamine solution 1.5% and purified water 80.48%.

AN 2006:795800 CAPLUS

DN 145:235790

TI Aqueous gel formulations containing immune response modifiers

IN Ma, David Q.; Perman, Christopher S.; Skwierczynski, Raymond D.

PA 3M Innovative Properties Company, USA

SO PCT Int. Appl., 123pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI	WO 2006084251	A2	20060810	WO 2006-US4201		20060203
	WO 2006084251	A3	20070405			
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA					
				US 2005-650030P	P	20050204
	AU 2006210392	A1	20060810	AU 2006-210392		20060203
				US 2005-650030P	P	20050204
				WO 2006-US4201	W	20060203
	CA 2597092	A1	20060810	CA 2006-2597092		20060203
				US 2005-650030P	P	20050204
				WO 2006-US4201	W	20060203
	EP 1844201	A2	20071017	EP 2006-720400		20060203

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU

			US 2005-650030P	P	20050204
			WO 2006-US4201	W	20060203
JP 2008530022	T	20080807	JP 2007-554306		20060203
			US 2005-650030P	P	20050204
			WO 2006-US4201	W	20060203
US 20090163532	A1	20090625	US 2008-883665		20080819
			US 2005-650030P	P	20050204
			WO 2006-US4201	W	20060203

IT 866649-05-0
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(aqueous gel formulations containing immune response modifiers)
RN 866649-05-0 CAPLUS
CN 1H-Imidazo[4,5-c]quinoline-1-butanamide, 4-amino-N,2-dipropyl- (CA INDEX NAME)



L4 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2009 ACS on STN
GI



I



II

AB Title compds. I [R1 = amide linked via alkyl, alkylene, or alkylalkylene;

R2 = H or a non-interfering substituent; R3 and R4 independently = H, halo, alkyl, alkoxy, etc.], pharmaceutical compns. containing the compds., intermediates, and methods of making and methods of use of these compds. as immunomodulators, for modulating cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases are disclosed. Thus, e.g., II was prepared by amidation of Et 4-(2-propyl-1H-imidazo[4,5-c]quinolin-1-yl)butanoate (preparation given) with morpholine and subsequent oxidation/amination. Methods are described for assaying cytokine induction (no data).

AN 2005:1103493 CAPLUS

DN 143:387036

TI Preparation of amide-substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines

IN Krepski, Larry R.; Dellaria, Joseph F., Jr.; Duffy, Daniel E.; Amos, David T.; Zimmermann, Bernhard M.; Moser, William H.

PA 3M Innovative Properties Company, USA

SO PCT Int. Appl., 234 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI	WO 2005094531	A2	20051013	WO 2005-US9880		20050324
	WO 2005094531	A3	20060309			
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
				US 2004-555753P	P	20040324
				US 2004-578769P	P	20040610
	AU 2005228150	A1	20051013	AU 2005-228150		20050324
				US 2004-555753P	P	20040324
				US 2004-578769P	P	20040610
				WO 2005-US9880	W	20050324
	CA 2559863	A1	20051013	CA 2005-2559863		20050324
				US 2004-555753P	P	20040324
				US 2004-578769P	P	20040610
				WO 2005-US9880	W	20050324
	EP 1730143	A2	20061213	EP 2005-731309		20050324
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR					
				US 2004-555753P	P	20040324
				US 2004-578769P	P	20040610
				WO 2005-US9880	W	20050324
	JP 2007530579	T	20071101	JP 2007-505186		20050324
				US 2004-578769P	P	20040610
				WO 2005-US9880	W	20050324
	US 20070219196	A1	20070920	US 2006-599159		20060921

			US 2004-555753P	P	20040324
			US 2004-578769P	P	20040610
			WO 2005-US9880	W	20050324
IN 2006CN03484	A	20070615	IN 2006-CN3484		20060922
			US 2004-555753P	P	20040324
			WO 2005-US9880	W	20050324

OS CASREACT 143:387036; MARPAT 143:387036
IT 1026420-75-6
RL: PRPH (Prophetic)
(Preparation of amide-substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines)
RN 1026420-75-6 CAPLUS
CN 1H-Imidazo[4,5-c]quinoline-1-butanamide, 4-amino-2-methyl- (CA INDEX NAME)



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2009 ACS on STN
GI



I



II

AB Title compds. [I; Z = -C(:N-OR2)- or CH-N(OR2)(YR3); X = CHR9,-CH(R9)-alk(en)ylene-, etc.; R9 = H, alkyl; R1 = H, (un)substituted alkyl, alkylene/hetero/aryl, etc.; R2, R3 = independently H, (un)substituted alk(en)yl, hetero/aryl, hetero/arylalkylenyl, etc.; Y = a bond, C:O, C:S, SO2, etc.; RA, RB = independently H, halo, alk(en)yl, etc.; RACCRB = (un)substituted fused hetero/aryl, fused 5-7-membered saturated ring], were prepared as immunomodulators for inducing cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases. For example, reacting 5-[4-Amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]pentan-2-one with NH2OH•HCl in the presence of NaBH3CN/AcOH/EtOH, and substitution with mesyl anhydride gave imidazoquinoline II (m.p. = 146-148°). Certain I may modulate cytokine biosynthesis by inhibiting production of tumor necrosis factor TNF-α when tested in mouse cells (no data).

AN 2005:493478 CAPLUS

DN 143:43875

TI Preparation of hydroxylamine and oxime substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines as inducers of cytokine biosynthesis for treatment of viral and neoplastic diseases

IN Krepski, Larry R.; Dellaria, Joseph F., Jr.; Duffy, Daniel E.; Amos, David T.; Zimmermann, Bernhard M.; Squire, David J.; Marszalek, Gregory J.; Heppner, Philip D.; Kshirsagar, Tushar A.

PA 3M Innovative Properties Company, USA

SO PCT Int. Appl., 305 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005051324	A2	20050609	WO 2004-US39673	20041124

WO 2005051324	A3	20060105				
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW						
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG						
			US 2003-524961P	P	20031125	
			US 2004-580139P	P	20040616	
			US 2004-581293P	P	20040618	
AU 2004293096	A1	20050609	AU 2004-293096		20041124	
			US 2003-524961P	P	20031125	
			US 2004-580139P	P	20040616	
			US 2004-581293P	P	20040618	
			WO 2004-US39673	W	20041124	
CA 2547085	A1	20050609	CA 2004-2547085		20041124	
			US 2003-524961P	P	20031125	
			US 2004-580139P	P	20040616	
			US 2004-581293P	P	20040618	
			WO 2004-US39673	W	20041124	
EP 1686992	A2	20060809	EP 2004-812235		20041124	
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS						
			US 2003-524961P	P	20031125	
			US 2004-580139P	P	20040616	
			US 2004-581293P	P	20040618	
			WO 2004-US39673	W	20041124	
CN 1905874	A	20070131	CN 2004-80040953		20041124	
			US 2003-524961P	P	20031125	
			US 2004-580139P	P	20040616	
			US 2004-581293P	P	20040618	
			WO 2004-US39673	W	20041124	
JP 2007512349	T	20070517	JP 2006-541442		20041124	
			US 2003-524961P	P	20031125	
			US 2004-580139P	P	20040616	
			US 2004-581293P	P	20040618	
			WO 2004-US39673	W	20041124	
US 20070099901	A1	20070503	US 2006-595859		20060518	
			US 2003-524961P	P	20031125	
			US 2004-580139P	P	20040616	
			US 2004-581293P	P	20040618	
			WO 2004-US39673	W	20041124	
IN 2006CN01847	A	20070608	IN 2006-CN1847		20060525	
			US 2003-524961P	P	20031125	
			WO 2004-US39673	W	20041124	
ZA 2006005216	A	20070425	ZA 2006-5216		20060623	
			US 2003-524961P	P	20031125	

PATENT FAMILY INFORMATION:

FAN 2005:490270

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

PI WO 2005051317 A2 20050609 WO 2004-US39512 20041124
WO 2005051317 A3 20060511
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
US 2003-524961P P 20031125
US 2004-580139P P 20040616

AU 2004293078 A1 20050609 AU 2004-293078 20041124
US 2003-524961P P 20031125
US 2004-580139P P 20040616
WO 2004-US39512 W 20041124

CA 2547020 A1 20050609 CA 2004-2547020 20041124
US 2003-524961P P 20031125
US 2004-580139P P 20040616
WO 2004-US39512 W 20041124

EP 1687307 A2 20060809 EP 2004-812098 20041124
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS
US 2003-524961P P 20031125
US 2004-580139P P 20040616
WO 2004-US39512 W 20041124

BR 2004016936 A 20070116 BR 2004-16936 20041124
US 2003-524961P P 20031125
US 2004-580139P P 20040616
WO 2004-US39512 W 20041124

CN 1926138 A 20070307 CN 2004-80040954 20041124
US 2003-524961P P 20031125
US 2004-580139P P 20040616
WO 2004-US39512 W 20041124

JP 2007512370 T 20070517 JP 2006-541697 20041124
US 2003-524961P P 20031125
US 2004-580139P P 20040616
WO 2004-US39512 W 20041124

SG 148201 A1 20081231 SG 2008-8728 20041124
US 2003-524961P P 20031125
US 2004-580139P P 20040616

MX 2006005910 A 20060823 MX 2006-5910 20060524
US 2003-524961P P 20031125
US 2004-580139P P 20040616
WO 2004-US39512 W 20041124

IN 2006CN01848 A 20070608 IN 2006-CN1848 20060525
US 2003-524961P P 20031125
WO 2004-US39512 W 20041124

KR 2006125818 A 20061206 KR 2006-712734 20060623
US 2003-524961P P 20031125
US 2004-580139P P 20040616
WO 2004-US39512 W 20041124

ZA 2006005216 A 20070425 ZA 2006-5216 20060623

US 2003-524961P P 20031125

FAN 2007:705671

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 20070149098	A1	20070628	US 2006-595959	20061113
US 7567855	B2	20090728		

US 2005-734989P P 20051110

OS CASREACT 143:43875; MARPAT 143:43875

IT 853010-62-5P, 4-(4-Amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)-1-phenylbutan-1-one
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of hydroxylamine and oxime substituted imidazoquinolines, imidazonaphthyridines, and imidazopyridines as inducers of cytokine biosynthesis for treatment of viral and neoplastic disease)

RN 853010-62-5 CAPLUS

CN 1-Butanone, 4-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)-1-phenyl- (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2009 ACS on STN

GI



I



II

AB Title compds. [I; X = alkylene optionally interrupted by one or more -O-; Z = C:O, - C(:O)O-, -C(OR3)2-; R1 = H, (un)substituted alkyl, alkylene/aryl, alkylene/heteroaryl; Q = O, S; R3 = (un)substituted alkyl, alkylene/aryl, alkylene/heteroaryl; R2 = H, (un)substituted alk(en/yn)yl, hetero/aryl, alkylenealkyl, etc.; RA, RB = independently H, halo, alk(en)yl, alkoxy, alkylthio, NH2 and derivs.; or RACCRB = (un)substituted fused aryl ring or fused 5-7-membered saturated ring; and their pharmaceutically acceptable salts], were prepared as immunomodulators for inducing cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases. For example, II was prepared by reacting 4-(2-Butyl-1H-imidazo[4,5-c]quinolin-1-yl)butyraldehyde (preparation given) with MeMgBr, followed by oxidation, reductive amination of the ketone, oxidation with m-CPBA/reaction with NH4OH. I have been found to induce cytokine biosynthesis by inhibiting production of tumor necrosis factor TNF-α when tested on an in vitro human blood cell system (no data).

AN 2005:490270 CAPLUS

DN 143:26611

TI Preparation of oxime substituted imidazo-containing compounds, particularly imidazoquinolines, as inducers of cytokine biosynthesis for treatment of viral and neoplastic diseases

IN Krepski, Larry R.; Dellaria, Joseph F., Jr.; Duffy, Daniel E.; Radmer, Matthew R.; Amos, David T.

PA 3M Innovative Properties Company, USA

SO PCT Int. Appl., 200 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005051317	A2	20050609	WO 2004-US39512	20041124
	WO 2005051317	A3	20060511		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,

CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO,
SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
NE, SN, TD, TG

				US 2003-524961P	P	20031125
				US 2004-580139P	P	20040616
AU	2004293078	A1	20050609	AU 2004-293078		20041124
				US 2003-524961P	P	20031125
				US 2004-580139P	P	20040616
				WO 2004-US39512	W	20041124
CA	2547020	A1	20050609	CA 2004-2547020		20041124
				US 2003-524961P	P	20031125
				US 2004-580139P	P	20040616
				WO 2004-US39512	W	20041124
EP	1687307	A2	20060809	EP 2004-812098		20041124

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS

				US 2003-524961P	P	20031125
				US 2004-580139P	P	20040616
				WO 2004-US39512	W	20041124
BR	2004016936	A	20070116	BR 2004-16936		20041124
				US 2003-524961P	P	20031125
				US 2004-580139P	P	20040616
				WO 2004-US39512	W	20041124
CN	1926138	A	20070307	CN 2004-80040954		20041124
				US 2003-524961P	P	20031125
				US 2004-580139P	P	20040616
				WO 2004-US39512	W	20041124
JP	2007512370	T	20070517	JP 2006-541697		20041124
				US 2003-524961P	P	20031125
				US 2004-580139P	P	20040616
				WO 2004-US39512	W	20041124
SG	148201	A1	20081231	SG 2008-8728		20041124
				US 2003-524961P	P	20031125
				US 2004-580139P	P	20040616
MX	2006005910	A	20060823	MX 2006-5910		20060524
				US 2003-524961P	P	20031125
				US 2004-580139P	P	20040616
				WO 2004-US39512	W	20041124
IN	2006CN01848	A	20070608	IN 2006-CN1848		20060525
				US 2003-524961P	P	20031125
				WO 2004-US39512	W	20041124
KR	2006125818	A	20061206	KR 2006-712734		20060623
				US 2003-524961P	P	20031125
				US 2004-580139P	P	20040616
				WO 2004-US39512	W	20041124
ZA	2006005216	A	20070425	ZA 2006-5216		20060623
				US 2003-524961P	P	20031125

PATENT FAMILY INFORMATION:
FAN 2005:493478

	PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI	WO 2005051324	A2	20050609	WO 2004-US39673		20041124
	WO 2005051324	A3	20060105			
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
				US 2003-524961P	P	20031125
				US 2004-580139P	P	20040616
				US 2004-581293P	P	20040618
	AU 2004293096	A1	20050609	AU 2004-293096		20041124
				US 2003-524961P	P	20031125
				US 2004-580139P	P	20040616
				US 2004-581293P	P	20040618
				WO 2004-US39673	W	20041124
	CA 2547085	A1	20050609	CA 2004-2547085		20041124
				US 2003-524961P	P	20031125
				US 2004-580139P	P	20040616
				US 2004-581293P	P	20040618
				WO 2004-US39673	W	20041124
	EP 1686992	A2	20060809	EP 2004-812235		20041124
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS					
				US 2003-524961P	P	20031125
				US 2004-580139P	P	20040616
				US 2004-581293P	P	20040618
				WO 2004-US39673	W	20041124
	CN 1905874	A	20070131	CN 2004-80040953		20041124
				US 2003-524961P	P	20031125
				US 2004-580139P	P	20040616
				US 2004-581293P	P	20040618
				WO 2004-US39673	W	20041124
	JP 2007512349	T	20070517	JP 2006-541442		20041124
				US 2003-524961P	P	20031125
				US 2004-580139P	P	20040616
				US 2004-581293P	P	20040618
				WO 2004-US39673	W	20041124
	US 20070099901	A1	20070503	US 2006-595859		20060518
				US 2003-524961P	P	20031125
				US 2004-580139P	P	20040616
				US 2004-581293P	P	20040618
				WO 2004-US39673	W	20041124
	IN 2006CN01847	A	20070608	IN 2006-CN1847		20060525
				US 2003-524961P	P	20031125
				WO 2004-US39673	W	20041124
	ZA 2006005216	A	20070425	ZA 2006-5216		20060623
				US 2003-524961P	P	20031125
FAN	2007:705671					

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20070149098	A1	20070628	US 2006-595959	20061113
	US 7567855	B2	20090728		
				US 2005-734989P P	20051110

OS CASREACT 143:26611; MARPAT 143:26611

IT 1045444-34-5
RL: PRPH (Prophetic)
(Preparation of oxime substituted imidazo-containing compounds, particularly imidazoquinolines, as inducers of cytokine biosynthesis for treatment of viral and neoplastic diseases)

RN 1045444-34-5 CAPLUS

CN 4-Decanone, 10-[4-amino-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]-2-methyl- (CA INDEX NAME)



OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2009 ACS on STN

AB Pharmaceutical formulations in an aqueous (preferably, sprayable) formulation including an immune response modifier (IRM), such as those chosen from imidazoquinoline amines, tetrahydroimidazoquinoline amines, imidazopyridine amines, 6,7-fused cycloalkylimidazopyridine amines, 1,2-bridged imidazoquinoline amines, imidazonaphthyridine amines, imidazotetrahydronaphthyridine amines, oxazoloquinoline amines, thiazoloquinoline amines, oxazolopyridine amines, thiazolopyridine amines, oxazolonaphthyridine amines, thiazolonaphthyridine amines, and 1H-imidazo dimers fused to pyridine amines, quinoline amines, tetrahydroquinoline amines, naphthyridine amines, or tetrahydronaphthyridine amines, are provided. In one embodiment, the aqueous formulations are advantageous for treatment and/or prevention of allergic rhinitis, viral infections, sinusitis, and asthma. For example, N-[2-[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]-1,1-dimethylethyl]methanesulfonamide (IRM 1) was prepared as a 0.375% aqueous solution capable of being nasally administered via a spray pump. The solution contained IRM 1 0.375%, CM-cellulose sodium 0.1%, benzalkonium chloride 0.02%, disodium EDTA 0.1%, L-lactic acid 1.53%, PEG 400 15%, 1N NaOH as needed for pH 4.0, and water to 100%. The IRM 1 solution (50 μL) administered to rats once 4 h before infection with humanized, non-lethal influenza virus, almost completely suppressed the virus. titer.

AN 2005:160991 CAPLUS
DN 142:246181
TI Formulations containing an amine-based immune response modifier
IN Hammerbeck, David M.; Guy, Cynthia A.; Leung, Suzanne S.
PA 3M Innovative Properties Company, USA
SO PCT Int. Appl., 118 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI	WO 2005016275	A2	20050224	WO 2004-US25277		20040805
	WO 2005016275	A3	20050414			
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
				US 2003-493109P	P	20030805
	AU 2004264336	A1	20050224	AU 2004-264336		20040805
				US 2003-493109P	P	20030805
				WO 2004-US25277	W	20040805
	CA 2534313	A1	20050224	CA 2004-2534313		20040805
				US 2003-493109P	P	20030805
				WO 2004-US25277	W	20040805
	US 20050070460	A1	20050331	US 2004-911800		20040805
				US 2003-493109P	P	20030805
	EP 1651190	A2	20060503	EP 2004-780166		20040805
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK					
				US 2003-493109P	P	20030805
				WO 2004-US25277	W	20040805
	JP 2007501252	T	20070125	JP 2006-522714		20040805
				US 2003-493109P	P	20030805
				WO 2004-US25277	W	20040805
	US 20070292456	A1	20071220	US 2006-595049		20060118
				US 2003-493109P	P	20030805
				WO 2004-US25277	W	20040805

PATENT FAMILY INFORMATION:
FAN 2005:158509

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005016273	A2	20050224	WO 2004-US25241	20040805
	WO 2005016273	A3	20051229		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,				

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

			US 2003-493109P	P	20030805
AU 2004264330	A1	20050224	AU 2004-264330		20040805
			US 2003-493109P	P	20030805
			WO 2004-US25241	W	20040805
CA 2534625	A1	20050224	CA 2004-2534625		20040805
			US 2003-493109P	P	20030805
			WO 2004-US25241	W	20040805
US 20050070460	A1	20050331	US 2004-911800		20040805
			US 2003-493109P	P	20030805
EP 1651216	A2	20060503	EP 2004-780131		20040805
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR					
			US 2003-493109P	P	20030805
			WO 2004-US25241	W	20040805
CN 1852711	A	20061025	CN 2004-80026603		20040805
			US 2003-493109P	P	20030805
			WO 2004-US25241	W	20040805
JP 2007501251	T	20070125	JP 2006-522709		20040805
			US 2003-493109P	P	20030805
			WO 2004-US25241	W	20040805

IT 845638-60-0
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(solns. containing amine-based immunomodulators)
RN 845638-60-0 CAPLUS
CN 1H-Imidazo[4,5-c]quinoline-1-butanamide, 4-amino-N-methoxy-N-methyl-2-propyl- (CA INDEX NAME)



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT